The efficacy of eribulin mesylate for patients with cutaneous angiosarcoma previously treated with taxane: a multi-center, prospective, observational study.

CONCLUSIONS: ERB showed a promising response rate and is a potential candidate for second-line treatment in CAS patient after taxane. However, the occurrence of SAEs in over a half of the participants, suggests caution about ERB use in elderly patients. PMID: 32198756 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/32198756?dopt=Abstract

Source: The British Journal of Dermatology - March 19, 2020 Category: Dermatology Authors: Fujisawa Y, Fujimura T, Matsushita S, Yamamoto Y, Uchi H, Otsuka A, Funakoshi T, Miyagi T, Hata H, Gosho M, Kambayashi Y, Aoki M, Yanagi T, Ohira A, Nakamura Y, Maeda T, Yoshino K Tags: Br J Dermatol Source Type: research